EFFECTIVENESS OF COLCHICINE IN PATIENTS WITH COVID-19 (Literature review)
Keywords:
cardiovascular disease (CVD), coronavirus infection COVID-19, colchicine, scale for assessing the clinical condition of the patient -COVIDAbstract
The article presents the results of the COLCORONA, KOLORIT, GRECCO-19 studies on the effectiveness of colchicine in the treatment of COVID-19.
References
Mareev V. Yu., Begrambekova Yu.L., Mareev Yu.V. How evaluate re- sults of treatment in patients with COVID-19? Symptomatic Hospital and Outpatient Clinical Scale for COVID-19 (scale for assessing the clinical condition of the patient -COVID). Kardiologiia. 2020;60(11):35–41. [Russian: Мареев В.Ю., Беграмбекова Ю.Л., Мареев Ю.В. Как оценивать результаты лечения больных с новой коронавирусной инфекцией (COV- ID-19)? Шкала Оценки Клинического Состояния (ШОКС–КОВИД). Кардиология. 2020;60(11):35-41]. DOI: 10.18087/car- dio.2020.11.n1439
Johns Hopkins Coronavirus Resource Center. Mortality Analyses. [In- ternet] Available at: https://coronavirus.jhu.edu/data/mortality
Mareev V.Yu., Orlova Ya.A., Pavlikova E.P., Matskeplishvili S.T., Akopyan Zh.A., Plisyk A.G. et al. Combination therapy at an ear-
ly stage of the novel coronavirus infection (COVID-19). Case series and design of the clinical trial “BromhexIne and Spironolactone for CoronаvirUs Infection requiring hospiTalization (BISCUIT)”. Kar- diologiia. 2020;60(8):4–15. [Russian: Мареев В.Ю., Орлова Я.А., Павликова Е.П., Мацкеплишвили С.Т., Акопян Ж.А., Плисюк А.Г. и др. Возможности комбинированной терапии на раннем этапе течения новой коронавирусной инфекции (COVID-19). Разбор клинических случаев и дизайн исследования: Бромгексин И Спиронолактон для лечения КоронаВирусной Инфекции, Требующей госпитализации (БИСКВИТ). Кардиология. 2020;60(8):4–15]. DOI: 10.18087/cardio.2020.8.n1307
Mareev V.Yu., Orlova Ya.A., Plisyk A.G., Pavlikova E.P., Matskeplish- vili S.T., Akopyan Zh.A. et al. Results of an open prospective con- trolled comparative study on the treatment of new coronavirus infec- tion (COVID-19): Bromhexine and spironolactone for the treatment of coronavirus Infection requiring hospitalization (BISCUIT). Kardiologiia. 2020;60(11):4–15. [Russian: Мареев В.Ю., Орлова Я.А., Плисюк А.Г., Павликова Е.П., Мацкеплишвили С.Т., Акопян Ж.А. и др. Результаты открытого проспективного контролируемого сравнительного исследования по лечению новой коронавирусной инфекции (COVID-19): Бромгексин И Спиронолактон для лечения КоронаВирусной Инфекции, Требующей госпитализации (БИСКВИТ). Кардиология. 2020;60(11):4-15]. DOI: 10.18087/ cardio.2020.11.1440
Mareev V.Yu., Orlova Ya.A., Pavlikova E.P., Akopyan Zh.A., Matskeplishvili S.T., Plisyk A.G. et al. Proactive anti-inflammatory and anticoagulant therapy in the treatment of advanced stages of nov- el coronavirus infection (COVID-19). Case Series and Study Design: COLchicine versus ruxolitinib and secukinumab in open prospective randomIzed trial (COLORIT). Kardiologiia. 2020;60(9):4–21. [Rus- sian: Мареев В.Ю., Орлова Я.А., Павликова Е.П., Акопян Ж.А., Мацкеплишвили С.Т., Плисюк А.Г. и др. Упреждающая противовоспалительная и антикоагулянтная терапия в лечении продвинутых стадий новой коронавирусной инфекции (COVID-19). Разбор клинических случаев и дизайн исследования: колхицин против руксолитиниба и секукинумаба в открытом проспективном рандомизируемом исследовании у пациентов с COVID-19 (КОЛОРИТ). Кардиология. 2020;60(9):4-21]. DOI: 10.18087/cardio.2020.9.n1338
Mareev V.Yu., Orlova Ya.A., Pavlikova E.P., Matskeplishvili S.T., Kras- nova T.N., Malahov P.S. et al. Steroid pulse -therapy in patients With coronAvirus Pneumonia (COVID-19), sYstemic inFlammation And Risk of vEnous thRombosis and thromboembolism (WAYFARER Study). Kardiologiia. 2020;60(6):15–29. [Russian: Мареев В.Ю., Орлова Я.А., Павликова Е.П., Мацкеплишвили С.Т., Краснова Т.Н., Малахов П.С. и др. Пульс-терапия стероидными гормонами больных с коронавирусной пневмонией (COVID-19), системным воспалением и риском венозных тромбозов и тромбоэмболий (исследование ПУТНИК). Кардиология. 2020;60(6):15-29]. DOI: 10.18087/cardio.2020.6.n1226
FitzGerald JD, Dalbeth N, Mikuls T, Brignardello‐Petersen R, Guy- att G, Abeles AM et al. 2020 American College of Rheumatology Guideline for the Management of Gout. Arthritis Care & Research. 2020;72(6):744–60. DOI: 10.1002/acr.24180
Kiselev Yu.Yu., Matveev A.V., Sychev D.A. Current and future use of colchicine in patients with COVID-19. Good Clinical Practice. 2020;4S:71–4. [Russian: Киселев Ю.Ю., Матвеев А.В., Сычев Д.А. Возможность и перспективы применения препарата колхицин у пациентов с COVID-19. Качественная Клиническая Практика. 2020;4S:71-4]. DOI: 10.37489/2588-0519-2020-S4-71-74
Tardif J-C, Kouz S, Waters DD, Bertrand OF, Diaz R, Maggioni AP
et al. Efficacy and Safety of Low-Dose Colchicine after Myocardial In- farction. New England Journal of Medicine. 2019;381(26):2497–505. DOI: 10.1056/NEJMoa1912388
Nidorf SM, Fiolet ATL, Mosterd A, Eikelboom JW, Schut A, Opstal TSJ et al. Colchicine in Patients with Chronic Coronary Disease. New England Journal of Medicine. 2020;383(19):1838–47. DOI: 10.1056/ NEJMoa2021372
Demidowich AP, Davis AI, Dedhia N, Yanovski JA. Colchicine to de- crease NLRP3-activated inflammation and improve obesity-related metabolic dysregulation. Medical Hypotheses. 2016; 92:67–73. DOI: 10.1016/j.mehy.2016.04.039
Yang M, Lv H, Liu Q, Zhang L, Zhang R, Huang X et al. Colchi- cine Alleviates Cholesterol Crystal-Induced Endothelial Cell Py- roptosis through Activating AMPK/SIRT1 Pathway. Oxidative Medicine and Cellular Longevity. 2020; 2020:9173530. DOI: 10.1155/2020/9173530
Martínez GJ, Celermajer DS, Patel S. The NLRP3 inflammasome and the emerging role of colchicine to inhibit atherosclerosis-associated inflammation. Atherosclerosis. 2018; 269:262–71. DOI: 10.1016/j. atherosclerosis.2017.12.027
Brunetti L, Diawara O, Tsai A, Firestein BL, Nahass RG, Poiani G et al. Colchicine to Weather the Cytokine Storm in Hospitalized Patients with COVID-19. Journal of Clinical Medicine. 2020;9(9):2961. DOI: 10.3390/jcm9092961
Montealegre-Gómez G, Garavito E, Gómez-López A, Rojas-Villarra- ga A, Parra-Medina R. Colchicine: A potential therapeutic tool against COVID-19. Experience of 5 patients. Reumatología Clínica. 2020; [Epub ahead of print]. DOI: 10.1016/j.reuma.2020.05.001
Lu Y, Chen J, Xiao M, Li W, Miller DD. An Overview of Tubulin Inhib- itors That Interact with the Colchicine Binding Site. Pharmaceutical Research. 2012;29(11):2943–71. DOI: 10.1007/s11095-012-0828-z
Deftereos SG, Giannopoulos G, Vrachatis DA, Siasos GD, Giotaki SG, Gargalianos P et al. Effect of Colchicine vs Standard Care on Cardiac and Inflammatory Biomarkers and Clinical Outcomes in Patients Hos- pitalized with Coronavirus Disease 2019: The GRECCO-19 Random- ized Clinical Trial. JAMA Network Open. 2020;3(6): e2013136. DOI: 10.1001/jamanetworkopen.2020.13136
University of Oxford. Randomised Evaluation of COVID-19 Therapy. ClinicalTrials.gov Identifier: NCT04381936. Av. at: https://clinical- trials.gov/ct2/show/NCT04381936. 2021.
U.S. National Library of Medicine. Anti-Coronavirus Therapies to Prevent Progression of COVID-19, a Randomized Trial. ClinicalTrials. gov Identifier: NCT04324463. Av. at: https://www.clinicaltrials.gov/ ct2/show/NCT04324463. 2020.
Tardif J-C, Bouabdallaoui N, L’Allier PL, Gaudet D, Shah B, Pillinger MH et al. Efficacy of Colchicine in Non-Hospitalized Patients with COVID-19. Av. at: http://medrxiv.org/lookup/doi/10.1101/2021.0 1.26.21250494. 2021.
Lomonosov Moscow State University Medical Research and Educa- tional Center. COLchicine Versus Ruxolitinib and Secukinumab In Open Prospective Randomized Trial (COLORIT). ClinicalTrials. gov Identifier: NCT04403243. Av. at: https://clinicaltrials.gov/ct2/ show/NCT04403243. 2020.
Lagunas-Rangel FA. Neutrophil-to-lymphocyte ratio and lympho- cyte-to-C-reactive protein ratio in patients with severe coronavirus disease 2019 (COVID-19): A meta-analysis. Journal of Medical Virol- ogy. 2020;92(10):1733–4. DOI: 10.1002/jmv.25819
Royal College of Physicians. National Early Warning Score (NEWS) 2. 2017. [Internet] Available at: https://www.rcplondon.ac.uk/projects/ outputs/national-early-warning-score-news-2
Liao X, Wang B, Kang Y. Novel coronavirus infection during the 2019–2020 epidemic: preparing intensive care units—the ex- perience in Sichuan Province, China. Intensive Care Medicine. 2020;46(2):357–60. DOI: 10.1007/s00134-020-05954-2
Landray M. Colchicine for non-hospitalised pts with COVID-19. Av. at: https://twitter.com/MartinLandray/status/13545053885829816 32?s=08. 2021.
Ullah W, Basyal B, Tariq S, Almas T, Saeed R, Roomi S et al. Lym- phocyte-to-C-Reactive Protein Ratio: A Novel Predictor of Adverse Outcomes in COVID-19. Journal of Clinical Medicine Research. 2020;12(7):415–22. DOI: 10.14740/jocmr4227
Kong M, Zhang H, Cao X, Mao X, Lu Z. Higher level of neutrophil-to- lymphocyte is associated with severe COVID-19. Epidemiology and Infection. 2020;148: e139. DOI: 10.1017/S0950268820001557
Karataş MB, İpek G, Onuk T, Güngör B, Durmuş G, Çanga Y et al. As- sessment of Prognostic Value of Neutrophil to Lymphocyte Ratio
and Platelet to Lymphocyte Ratio in Patients with Pulmonary Embo- lism. Acta Cardiologica Sinica. 2016;32(3):313–20. DOI: 10.6515/ acs20151013a
Zhang Y, Wu W, Du M, Luo W, Hou W, Shi Y et al. Neutrophil-to- Lymphocyte Ratio may Replace Chest Computed Tomography to Re- flect the Degree of Lung Injury in Patients with Corona Virus Disease 2019 (COVID-19). Av. at: https://www.researchsquare.com/article/ rs-23201/v1. DOI: 10.21203/rs.3.rs-23201/v1. 2020.
Feng Z, Yu Q, Yao S, Luo L, Zhou W, Mao X et al. Early predic- tion of disease progression in COVID-19 pneumonia patients with chest CT and clinical characteristics. Nature Communications. 2020;11(1):4968. DOI: 10.1038/s41467-020-18786-x
Vernadsky R.Yu., Medvedeva A.A., Garbukov E.Yu., Sinilkin I.G., Bragina O.D., Zelchan R.V. et al. Single-photon emission com- puted tomography with 99mTc-1-thio-d-glucose for metabolic breast cancer imaging. Russian Electronic Journal of Radiology. 2019;9(4):82–96. [Russian: Вернадский Р.Ю., Медведева А.А., Гарбуков Е.Ю., Синилкин И.Г., Брагина О.Д., Зельчан Р.В. и др. Метаболическая визуализация рака молочной железы методом однофотонной эмиссионной компьютерной томографии с 99mTc- 1-тио-d-глюкозой. Российский Электронный Журнал Лучевой Диагностики. 2019;9(4):82-96]. DOI: 10.21569/2222-7415-2019- 9-4-82-96
